Cover Image
市場調查報告書

Poly (ADP核糖) 聚合酵素1 (ADP核糖基轉移酶白喉毒素樣1,PARP-1,NAD (+) ADP-核糖基轉移酶1,ADPRT 1,Poly (ADP核糖) 合成酶1,EC 2.4.2.30):開發中產品分析

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 363570
出版日期 內容資訊 英文 155 Pages
訂單完成後即時交付
價格
Back to Top
Poly (ADP核糖) 聚合酵素1 (ADP核糖基轉移酶白喉毒素樣1,PARP-1,NAD (+) ADP-核糖基轉移酶1,ADPRT 1,Poly (ADP核糖) 合成酶1,EC 2.4.2.30):開發中產品分析 Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H1 2018
出版日期: 2018年04月17日 內容資訊: 英文 155 Pages
簡介

本報告提供全球各國的Poly (ADP核糖) 聚合酵素1 (別名ADP核糖基轉移酶白喉毒素樣1、PARP-1、NAD (+) ADP-核糖基轉移酶1、ADPRT 1、Poly (ADP核糖) 合成酶1或EC 2.4.2.30) 相關的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊 ,為您概述為以下內容。

目錄

  • 簡介
    • 分析範圍
  • Poly (ADP核糖) 聚合酵素1 (ADP核糖基轉移酶白喉毒素樣1、PARP-1、NAD (+) ADP-核糖基轉移酶1、ADPRT 1、Poly (ADP核糖) 合成酶1、EC 2.4.2.30)的概要
  • 治療藥的開發情形
    • 臨床實驗的各階段
    • 各治療領域
    • 各症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 各企業開發中的治療藥
  • 各大學、研究機關開發中的治療藥
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥法
    • 各分子類型
  • 開發治療藥的企業
    • AbbVie Inc.
    • American Gene Technologies International Inc.
    • AstraZeneca Plc
    • BeiGene, Ltd.
    • Clovis Oncology, Inc.
    • Eisai
    • Hager Biosciences, LLC
    • IMPACT Therapeutics, Inc.
    • Jeil Pharmaceutical Co., Ltd.
    • Jiangsu Hengrui Medicine Co., Ltd.
    • 田邊三菱製藥
    • Nerviano Medical Sciences S.r.l.
    • 武田藥品工業
    • Tesaro, Inc.
    • Teva Pharmaceutical Industries Ltd.
  • 藥物簡介
    • ABT-767
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的發展情形
    • AGPD
    • AZ-0108
    • BGB-290
    • CK-102
    • E-7449
    • fluzoparib
    • IMP-04297
    • JPI-289
    • MP-124
    • niraparibu
    • NMSP-118
    • NMSP-648
    • NMSP-914
    • oraparibu
    • R-503
    • 磷酸rukaparibu (rucaparib phosphate)
    • 有機磷酸中毒的PARP-1抑制用/AChE活性化用小分子
    • 未公開的症狀的PARP-1抑制用小分子
    • 結腸癌症的PARP-1抑制用小分子
    • 腫瘤的PARP-1/-2/-3及一氧化氮 (NO) 標的小分子
    • veliparib
    • XZ-120312
    • YHP-743
  • 開發暫停的產品
  • 開發中止的產品
  • 值得注意的最新趨勢、新聞稿 (共15件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1415TDB

Summary

According to the recently published report 'Poly [ADP Ribose] Polymerase 1 - Pipeline Review, H1 2018'; Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) pipeline Target constitutes close to 31 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes.

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Poly [ADP-ribose] polymerase 1 (PARP-1) is an enzyme encoded by the PARP1 gene.

It is involved in the base excision repair (BER) pathway, by catalyzing the poly (ADP-ribosylation) of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism.

It positively regulates the transcription of MTUS1 and negatively regulates the transcription of MTUS2/TIP150. It is required for PARP9 and DTX3L recruitment to DNA damage sites. PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites.

The report 'Poly [ADP Ribose] Polymerase 1 - Pipeline Review, H1 2018' outlays comprehensive information on the Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 5, 9, 1, 4 and 3 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Immunology, Respiratory, Toxicology and Undisclosed which include indications Ovarian Cancer, Breast Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Metastatic Breast Cancer, Small-Cell Lung Cancer, Solid Tumor, Gastric Cancer, Epithelial Ovarian Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Glioblastoma Multiforme (GBM), Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Cervical Cancer, Malignant Mesothelioma, Mantle Cell Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Transitional (Urothelial) Tract Cancer, Non-Hodgkin Lymphoma, Prostate Cancer, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), B-Cell Chronic Lymphocytic Leukemia, Bladder Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Essential Thrombocythemia, Ewing Sarcoma, Follicular Lymphoma, Germ Cell Tumors, Germinomatous (Seminomatous) Germ Cell Tumors, Glioma, Gynecological Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Laryngeal Cancer, Leiomyosarcoma, Lung Cancer, Lung Injury, Lung Transplant Rejection, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Prostate Cancer, Muscle Invasive Bladder Cancer (MIBC), Myelofibrosis, Neuroblastoma, Neuroendocrine Tumors, Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Organophosphate and Carbamate Poisoning, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Peritoneal Tumor, Polycythemia Vera, Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Soft Tissue Sarcoma, Squamous Non-Small Cell Lung Cancer, Testicular Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Traumatic Brain Injury, Unspecified and Uveal Melanoma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30)
  • The report reviews Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Overview
  • Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • American Gene Technologies International Inc
  • AstraZeneca Plc
  • BeiGene Ltd
  • Checkpoint Therapeutics Inc
  • Clovis Oncology Inc
  • Hager Biosciences LLC
  • Ildong Pharmaceutical Co Ltd
  • IMPACT Therapeutics Inc
  • Jeil Pharmaceutical Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Nerviano Medical Sciences Srl
  • Shanghai Acebright Pharmaceuticals Group Co Ltd
  • Tasly Pharmaceutical Group Co Ltd
  • Tesaro Inc
  • Teva Pharmaceutical Industries Ltd
  • Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Drug Profiles
  • 2X-121 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ABT-767 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AG-PD - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AZ-0108 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AZD-1775 + olaparib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AZD-6738 + olaparib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cediranib maleate + olaparib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CK-102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IDX-1197 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IMP-4297 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JPI-289 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MP-124 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • niraparib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NMSP-118 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NMSP-293 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • olaparib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pamiparib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • R-554 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rucaparib camsylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SC-10914 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SHR-3162 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit PARP-1 for Unspecified Indication - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit PARP1 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Target PARP1, 2, 3 and NO for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SOMCL-9112 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tislelizumab + pamiparib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TSL-1502 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • veliparib ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XZ-120312 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • YHP-743 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Dormant Products
  • Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Discontinued Products
  • Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Product Development Milestones
  • Featured News & Press Releases
  • Apr 06, 2018: Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer
  • Apr 03, 2018: The European Medicines Agency Accepts Regulatory Submission for Lynparza in BRCA-mutated HER2-Negative Metastatic Breast Cancer
  • Apr 02, 2018: Myriad Receives Pre-Market Approval for its BRACAnalysis Diagnostic System in Japan
  • Mar 26, 2018: Data from TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian Cancer
  • Mar 26, 2018: EMA Recommends Granting a Conditional Marketing Authorisation for Rucaparib
  • Mar 14, 2018: TESARO to Present Data on ZEJULA at AACR 2018 Annual Meeting
  • Mar 08, 2018: Clovis Oncology Announces Notice of Allowance for Rucaparib High Dosage Strength Tablet Patent with Expiration in 2035
  • Feb 27, 2018: TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results
  • Feb 23, 2018: Lynparza receives positive EU CHMP opinion in platinum-sensitive relapsed ovarian cancer
  • Feb 21, 2018: Clovis Oncology Receives Positive Trend Vote from CHMP in European Regulatory Review for Rucaparib Ovarian Cancer Treatment Indication
  • Feb 08, 2018: Once a day pill for ovarian cancer could be made available on the CDF
  • Feb 05, 2018: Newcastle University Provides Update on Anti-Neoplastic Agent Rucaparib
  • Jan 19, 2018: Lynparza receives approval in Japan for the treatment of advanced ovarian cancer
  • Jan 12, 2018: LYNPARZA (olaparib) Approved by US FDA in Germ line BRCA-mutated Metastatic Breast Cancer
  • Jan 03, 2018: Myriad Genetics Announces Expanded Research Collaboration with AstraZeneca
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..5), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..6), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..7), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..8), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..9), H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by AbbVie Inc, H1 2018
  • Pipeline by American Gene Technologies International Inc, H1 2018
  • Pipeline by AstraZeneca Plc, H1 2018
  • Pipeline by BeiGene Ltd, H1 2018
  • Pipeline by Checkpoint Therapeutics Inc, H1 2018
  • Pipeline by Clovis Oncology Inc, H1 2018
  • Pipeline by Hager Biosciences LLC, H1 2018
  • Pipeline by Ildong Pharmaceutical Co Ltd, H1 2018
  • Pipeline by IMPACT Therapeutics Inc, H1 2018
  • Pipeline by Jeil Pharmaceutical Co Ltd, H1 2018
  • Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
  • Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018
  • Pipeline by Nerviano Medical Sciences Srl, H1 2018
  • Pipeline by Shanghai Acebright Pharmaceuticals Group Co Ltd, H1 2018
  • Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2018
  • Pipeline by Tesaro Inc, H1 2018
  • Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018
  • Dormant Products, H1 2018
  • Dormant Products, H1 2018 (Contd..1), H1 2018
  • Dormant Products, H1 2018 (Contd..2), H1 2018
  • Discontinued Products, H1 2018
  • Discontinued Products, H1 2018 (Contd..1), H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top